Palatin Technologies Inc (PTN): Cash & Equivalents
$7.49M
As of 2026-06-30
$3.74M
As of 2026-09-30
-12.0%
3-year compound annual growth
-34.1%
5-year compound annual growth
-0.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $7.49M | +192.2% | 2026-09-28, Balance as of period end |
| 2025-06-30 | $2.56M | -73.1% | 2026-09-28, Balance as of period end |
| 2024-06-30 | $9.53M | -13.2% | 2024-09-30, Balance as of period end |
| 2023-06-30 | $10.98M | -63.3% | 2023-09-28, Balance as of period end |
| 2022-06-30 | $29.94M | -50.2% | 2022-09-22, Balance as of period end |
| 2021-06-30 | $60.10M | -27.5% | 2022-09-22, Balance as of period end |
| 2020-06-30 | $82.85M | +90.4% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $43.51M | +14.5% | 2020-09-25, Balance as of period end |
| 2018-06-30 | $38.00M | -5.5% | 2020-09-25, Balance as of period end |
| 2017-06-30 | $40.20M | +402.3% | 2020-09-25, Balance as of period end |
| 2016-06-30 | $8.00M | -70.7% | 2018-09-13, Balance as of period end |
| 2015-06-30 | $27.30M | +124.0% | 2017-09-25, Balance as of period end |
| 2014-06-30 | $12.18M | -36.4% | 2016-09-19, Balance as of period end |
| 2013-06-30 | $19.17M | +400.8% | 2015-09-18, Balance as of period end |
| 2012-06-30 | $3.83M | -79.7% | 2014-09-12, Balance as of period end |
| 2011-06-30 | $18.87M | +249.1% | 2013-09-27, Balance as of period end |
| 2010-06-30 | $5.41M | n/a | 2012-09-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Palatin Technologies Inc (PTN) | 2026-06-30 | $7.49M | +192.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $15.42M | -20.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.01M | -50.4% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
Compare PTN, TNXP, EVMN, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗